The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and peritoneal carcinomatosis or positive peritoneal cytology.
 
Brian D. Badgwell
No Relationships to Disclose
 
Mariela A. Blum-Murphy
No Relationships to Disclose
 
Naruhiko Ikoma
No Relationships to Disclose
 
Jeannelyn Estrella
No Relationships to Disclose
 
Jenny Jing Li
No Relationships to Disclose
 
Jitesh D. Kawedia
No Relationships to Disclose
 
Paul F. Mansfield
Stock and Other Ownership Interests - Amgen; LabCorp; Stryker
Patents, Royalties, Other Intellectual Property - Royalties for up to date
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Arcus Biosciences; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Insys Therapeutics; Merck; Novartis; SERVIER; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly